Azithromycin for Malaria?
Author(s) -
Philip J. Rosenthal
Publication year - 2016
Publication title -
american journal of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.015
H-Index - 151
eISSN - 1476-1645
pISSN - 0002-9637
DOI - 10.4269/ajtmh.16-0332
Subject(s) - artemisinin , piperaquine , malaria , dihydroartemisinin , medicine , azithromycin , combination therapy , drug resistance , infectious disease (medical specialty) , plasmodium falciparum , intensive care medicine , disease , pharmacology , biology , immunology , antibiotics , microbiology and biotechnology
Malaria continues to be one of the greatest infectious disease problems in the world. Antimalarial drugs play an essential role in the treatment and control of malaria. For treatment, older drugs are limited by resistance, but artemisinin-based combination therapy remains highly effective in most areas. However, artemisinin resistance has emerged in southeast Asia, and resistance to artemisinin partner drugs is already common in many areas. In Cambodia, where resistance to both artemisinins and piperaquine is prevalent, frequent failures after treatment with dihydroartemisinin-piperaquine have been seen. We can anticipate that artemisinin resistance will spread to other areas, and that resistance to artemisinins and partner drugs will seriously threaten our ability to treat malaria.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom